EN
HI
Lupin Share price
LUPIN
2250.3
30.70 (-1.35%)NSE
BSE
Last updated on 13 Aug, 2026 | 15:52 IST
Lupin share price chart
Lupin Share Key Metrics
Volume
5.83 L
Market Cap
102891.04 CR
LTQ@LTP
8@2250.30
ATP
2260.22
Var Margin
12.57 %
Circuit Range
2052.9-2509.1
Delivery %
59.83 %
Value
131.77 CR
ASM/GSM
No
Market Lot
1
Summary
LUPIN stock price is ₹2250.3 as of 14 Aug, 2026. The stock intraday movement has stayed between ₹2250.30 and ₹2278.00, while Lupin share price 52 week high low is ₹1875.00 & ₹2529.50.
In terms of trading activity, LUPIN share price has recorded a volume of 5,83,016 shares. The Lupin has a market cap of ₹457232536. The stock’s Average Traded Price (ATP) stands at ₹2260.22, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 8 @ ₹2250.30.
The Lupin upper circuit limit is ₹2509.10 & The Lupin lower circuit limit is ₹2052.90, with a Value of ₹131.77 CR. The Delivery Percentage for the day is 59.83%.
Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.
Lupin Resistance and Support
Pivot 2272.77
Resistance
First Resistance
2296.04
Second Resistance
2311.07
Third Resistance
2334.34
Support
First Support
2257.74
Second Support
2234.47
Third Support
2219.44
Lupin Futures & Options
2250.3
-30.7 (-1.35%)
Lupin Option Chain
View Price, OI, Greeks & More...
25AUG26
2260.10
-10.20 (0.45%)
29SEP26
2271.80
-9.60 (0.42%)
27OCT26
2286.10
-7.80 (0.34%)
LUPIN|25AUG26 CE 2240.00
46.60
-9.75 (-17.3%)
LUPIN|25AUG26 PE 2260.00
35.1
2.05 (6.2%)
Lupin Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2025-26
- 2024-25
- 2026-27
Total Promoters
Segment
Percent
Total Promoters
46.95%
Mutual Fund
16.92%
Insurance
6.41%
Foreign Institutional Investors
22.04%
Domestic Institutional Investors
1.42%
Retail
6.26%
Others
0%
Total Promoters
MAR '24
47.01%
JUN '24
46.98%
SEP '24
46.96%
DEC '24
46.95%
Lupin Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-06 | Quarterly Results |
| 2026-05-07 | Audited Results & Final Dividend |
| 2026-02-12 | Quarterly Results |
| 2025-11-06 | Quarterly Results & Others |
| 2025-08-05 | Quarterly Results & Others |
| 2025-05-14 | Audited Results & Final Dividend |
| 2025-02-11 | Quarterly Results & Others |
| 2024-11-07 | Quarterly Results |
| 2024-08-06 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-17 | 2026-07-17 | View More |
Lupin News
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Lupin Limited will participate in five analyst and institutional investor meetings scheduled from August 13 to September 1, 2026. These meetings are in-person group sessions.
Aug 10 2026 16:19:59
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Lupin announced that the audio recording of the earnings call for Q1 FY27 Results, conducted on August 07, 2026, is available on its website for investor access.
Aug 07 2026 21:30:22
Lupin Ltd - 500257 - Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Lupin's Board approved Q1 FY27 consolidated financial results. Revenue from operations increased to ₹8,276.89 crores, up 31.06% YoY, while net profit grew 15.96% YoY to ₹1,416.98 crores. The company completed the acquisition of VISUfarma B.V. for ₹2,090.27 crores during the quarter.
Aug 06 2026 21:56:30
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Limited secured US FDA approval for Diazepam Injection USP, 10 mg/2 mL, expanding its product offering in the US market. This product addresses anxiety disorders, with estimated annual sales of $77.9 million.
Jul 31 2026 17:06:47
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin has announced US FDA approval for its Sugammadex Injection, followed by its launch in the United States. This product is bioequivalent to Merck's Bridion® Injection and is indicated for reversing neuromuscular blockade.
Jul 31 2026 11:16:04
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Lupin will conduct an Earnings Call for Q1 FY27 on August 07, 2026, at 4:30 PM IST. The call will discuss the company's financial results and provide an update on operations.
Jul 22 2026 18:49:17
Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Lupin's Board will meet on August 06, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026. This meeting is for the upcoming Q1 FY27 earnings.
Jul 22 2026 16:35:37
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Acquisition
Lupin Inc., a wholly-owned subsidiary, acquired an 82.2% equity stake in Kaveri Therapeutics, Inc. by licensing two oncology programs. This strategic move aims to advance the programs through global clinical trials and secure additional funding.
Jul 21 2026 07:13:06
Read More
Lupin Management
| Name | Position |
|---|---|
| Manju D Gupta | Chairperson |
| Nilesh Gupta | Managing Director |
Lupin Similar Stocks
Divi's Laboratories Ltd.
8500.00
-100.00 (1.16%)
Torrent Pharmaceuticals Ltd.
4914.50
21.50 (0.44%)
Apollo Hospitals Enterprise Ltd.
8600.00
3.00 (0.03%)
Cipla Ltd.
1458.80
-4.20 (0.29%)
Zydus Lifesciences Ltd.
1167.30
-37.70 (3.13%)
Lenskart Solutions Ltd.
596.90
10.45 (1.78%)
Max Healthcare Institute Ltd.
1013.30
5.80 (0.58%)
Dr. Reddy's Laboratories Ltd.
1206.00
6.00 (0.50%)
Laurus Labs Ltd.
1851.70
1.70 (0.09%)
Mankind Pharma Ltd.
2404.40
-28.70 (1.18%)
Lupin FAQs
The Buying Price of Lupin share is 2250.3 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Lupin stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Lupin, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Lupin shares is 18.73. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Lupin shares is 4.35. Useful to assess the stock's value relative to its book value.
To assess Lupin’s valuation compare Sector P/E, P/B which are 64.16 & 3.28 with sector averages, along with growth rates and financial metrics.
The Market Cap of Lupin is 102891.04 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Lupin share price is 2529.50 & 1875.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Lupin belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Invest in LUPIN
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC